Ligand Pharmaceuticals (LGND) Capital Leases (2010 - 2015)

Ligand Pharmaceuticals has disclosed Capital Leases across 6 years of filings, most recently posting $228000.0 for Q2 2015.

• Capital Leases for Q2 2015 came in at $228000.0, down 85.63% year-over-year; the trailing twelve-month figure through Jun 2015 was $228000.0 (down 85.63% YoY), and the FY2014 annual result was $934000.0, down 69.59% from the prior year.
• Capital Leases came in at $228000.0 for Q2 2015 at Ligand Pharmaceuticals, down from $577000.0 in the prior quarter.
• In the past five years, Capital Leases ranged from a high of $9.9 million in Q2 2011 to a low of $228000.0 in Q2 2015.
• The 5-year median for Capital Leases is $4.0 million (2013), against an average of $4.4 million.
• Across the five-year window, Capital Leases slipped 24.74% in 2011 and sank 85.63% in 2015, its largest moves.
• Ligand Pharmaceuticals' Capital Leases stood at $8.4 million in 2011, then retreated by 28.73% to $6.0 million in 2012, then plunged by 48.5% to $3.1 million in 2013, then slumped by 69.59% to $934000.0 in 2014, then plunged by 75.59% to $228000.0 in 2015.
• The last three Capital Leases figures came in at $228000.0 (Q2 2015), $577000.0 (Q1 2015), and $934000.0 (Q4 2014), per Business Quant data.